Rafigrelide is primarily utilized in the field of medical research and pharmacology for its potential antiplatelet and antithrombotic properties. It is being studied for its ability to inhibit platelet aggregation, which makes it a candidate for the prevention and treatment of thrombotic disorders such as heart attacks and strokes. Researchers are exploring its efficacy in reducing the risk of blood clot formation in patients with cardiovascular diseases. Additionally, its mechanism of action is of interest for developing new therapeutic strategies to manage conditions related to abnormal blood clotting. Clinical trials and preclinical studies are ongoing to assess its safety, effectiveness, and potential applications in human medicine.